




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|--|--|--|---|
| (51) International Patent Classification 7 : A61K 47/48, 51/10, A61P 35/00 | | A1 | (11) International Publication Number: WO 00/50086 |
| | | | (43) International Publication Date: 31 August 2000 (31.08.00) |
| (21) International Application Number: PCT/EP00/01553 | | (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). | |
| (22) International Filing Date: 24 February 2000 (24.02.00) | | <p>Published</p> <p><i>With international search report.</i></p> <p><i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> | |
| (30) Priority Data: 60/121,340 24 February 1999 (24.02.99) US 99200754.2 12 March 1999 (12.03.99) EP | | | |
| (71) Applicant (for all designated States except US): MALLINCK-RODT INC. [US/US]; 675 McDonnell Boulevard, St. Louis, MO 63134 (US). | | | |
| (72) Inventors; and (75) Inventors/Applicants (for US only): ALBERTO, Roger, Ariel [CH/CH]; St. Georgenstrasse 54, CH-8400 Winterthur (CH). SCHIBLI, Roger [CH/CH]; Bernastrasse 343, CH-5325 Leibstadt (CH). | | | |
| (74) Agent: ARNOLD & SIEDSMA; Sweelinckplein 1, NL-2517 The Hague (NL). | | | |

(54) Title: MOLECULES FOR THE TREATMENT AND DIAGNOSIS OF TUMORS



(57) Abstract

The invention relates to molecules for treatment and diagnosis of tumors and malignancies, comprising a tumor seeking biomolecule, which is coupled to an intercalating moiety, which is capable of complexing a metal, which metal is preferably a radioactive metal, to the use of these molecules and to therapeutic and diagnostic compositions containing them.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|--|----|--|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | | | TR | Turkey |
| BG | Bulgaria | HU | Hungary | ML | Mali | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MN | Mongolia | UA | Ukraine |
| BR | Brazil | IL | Israel | MR | Mauritania | UG | Uganda |
| BY | Belarus | IS | Iceland | MW | Malawi | US | United States of America |
| CA | Canada | IT | Italy | MX | Mexico | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NE | Niger | VN | Viet Nam |
| CG | Congo | KE | Kenya | NL | Netherlands | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NO | Norway | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | NZ | New Zealand | | |
| CM | Cameroon | KR | Republic of Korea | PL | Poland | | |
| CN | China | | | PT | Portugal | | |
| CU | Cuba | KZ | Kazakstan | RO | Romania | | |
| CZ | Czech Republic | LC | Saint Lucia | RU | Russian Federation | | |
| DE | Germany | LI | Liechtenstein | SD | Sudan | | |
| DK | Denmark | LK | Sri Lanka | SE | Sweden | | |
| EE | Estonia | LR | Liberia | SG | Singapore | | |

MOLECULES FOR THE TREATMENT AND DIAGNOSIS OF TUMOURS

The present invention relates to new molecules for the treatment and diagnosis of tumors. The invention furthermore relates to therapeutical compositions comprising one or more of these molecules and to the use
5 of both in treatment and diagnosis of cancer.

The diagnosis and therapy of cancer still requires a large input from the pharmaceutical and chemical industry. Although a substantial effort is made to develop new treatments, there are still many tumor
10 types for which no treatment exists. An additional problem is the formation of micrometastases, which cannot be diagnosed or treated.

An important problem in treatment is the similarity between normal cells and cancer cells.
15 Treatments interfering with the growth of tumor cells will also interfere in the growth of healthy cells. Radiotherapy as it is now known consists essentially of an arbitrary cross-fire from outside the cell or the cytoplasm. Because this is a rather rough treatment
20 surrounding cells and tissues might also be damaged leading to more or less severe side effects.

The provision of an improved radiotherapy and diagnostic method for cancer which uses very low amounts of radionuclides and leads to a direct treatment in the
25 malignant cell is therefore highly desirable.

It is known that the metabolism of cancer cells differs from that of normal cells. In addition, cancer cells appear to have an increased membrane permeability in comparison to normal cells due to an increased
30 expression of membrane receptors. The result is that the cancer cells are more permeable for biological vectors, like proteins and peptides.

The enhanced uptake of such biological vectors can be used in the diagnosis of tumors by binding a

radionuclide to a protein, for example by iodination of tyrosine functions in the protein or by covalent coupling of radioactive metal complexes. These molecules combine a tumor seeking function and a radioactive function.

- 5 Although these types of molecules have been used for diagnosis, their use in therapy was not yet described.

It is the object of the present invention to further improve on the above described molecules to come to an even better tailored treatment of malignant cells.

- 10 This object is achieved by the invention by the provision of a molecule in which three functions are combined. This molecule comprises a tumor seeking molecule, which is coupled to an intercalating moiety, which is capable of complexing a metal, which metal is
15 preferably a radioactive metal. The molecule can be targeted specifically to the tumor by the tumor seeking molecule and be internalized by the cell. The intercalating moiety will then insert into the DNA strand and induce breaks. In addition, the radioactive metal
20 will also lead to strand breaking of the DNA. The advantage of the new molecules is that they are specifically directed to the malignant cell and are taken up by the cell.

- The tumor seeking molecule is preferably a
25 biomolecule, such as a peptide or protein that is actively targeted to the tumor cell. Examples of these biomolecules are somatostatin-, neurotensin-, bombesin-receptor binding molecules, monoclonal antibodies, penetratinesTM, and glycoproteins, and molecules binding
30 to the GPIIb/IIIa receptors. The invention is however not limited to these examples and is more generally applicable to other tumor seeking agents as well. This category encompasses in addition compounds which are known to be transported into the nucleus or the nucleus
35 membrane. Examples of these are anti-sense oligonucleotides, proliferating agents, like deoxy-uridine, and small molecules, like spermidine.

The intercalating moiety is preferably an aromatic molecule with an intercalative binding affinity

for double-stranded DNA. Examples of such aromatic compounds are compounds containing i.e. acridine, porphyrin, ellipticine, phenantroline, carbazole, benzimidazole or compounds with known cytostatic activity (antibiotics) from the class of tetracyclines (anthracyclines), such as daunorubicine, epirubicine or mixoxantrone and are functionalized with ligands able to coordinate the $[M(CO)_3]^+$ moiety. Examples of such ligands are those mentioned in EP-879 606 and additionally polyamino-polycarboxylates, phosphates and phosphonates, aliphatic or aromatic or mixed triamines and thiones.

The intercalating and tumor seeking functions are sometimes combined in existing molecules. Examples of intercalating agents combining an intercalating moiety and a peptide are actinomycin and triostin.

The radioactive molecule can be any radioisotope. Pure γ -emitting nuclides are preferred since their accompanying low range conversion electrons will lead to cleavage of bonds, which are close to the decaying nucleus. The dose burden to the patient remains thus very low.

Particularly suitable combinations of the three functions are given in Fig. 1.

The invention further relates to the use of the molecules in therapy and diagnosis and to therapeutical and diagnostic compositions comprising one or more of these molecules.

Therapeutical compositions comprise at least a suitable amount of the molecule in a diluent or excipient. Such compositions can take the form of solutions and are administered intravenously, intraperitoneally or intrathecally. Suitable amounts to be administered depend on the way of administration, the radionuclide used and the indication to be treated or diagnosed. Suitable amounts vary between 10^{-9} and 10^{-1} g per kg body weight.

Excipients and diluents for this type of medication are well known to the skilled person. However,

the present molecules require certain conditions for stability. Preferably, the excipient or diluent should be of a hydrophilic and preferably organic nature.

For diagnostic purposes the composition
5 consists of at least a suitable amount of the molecule in a diluent or excipient. Diagnostic methods to be used with the composition of the invention are scintigraphy or Magnetic Resonance Imaging (MRI).

It was now found that the method for the
10 synthesis of Tc and Re carbonyls from water described in EP-879 606 is suitable for preparation of the molecules of the invention. It is in particular possible with this method to introduce intercalating ligands, which form very stable complexes (in vitro and in vivo) with the
15 above mentioned carbonyls. EP-879 606 is incorporated herein by reference.

The ligands claimed in EP-879 606 and acridine, porphyrin, ellipticine, phenantroline, carbazole, benzimidazole do stabilize the $\text{fac-}[\text{Tc}(\text{CO})_3]^+$ moiety in
20 serum and form complexes at very low concentrations. These ligands can be site specifically attached to the biomolecules and subsequently be labeled with i.e. Tc-99m. Since the radionuclide is very close to the intercalating ligand, its low energy electron will penetrate the
25 DNA-strands very well and induce strandbreaking. When intercalating in one of the grooves, the probability to hit is very high since the nucleus is practically surrounded by DNA.

The biomolecules derivatized according to the
30 invention exhibit high selectivity and are internalized. As known from pure organic intercalators, the complex is going to intercalate in DNA in particular when the cell is dividing. In contrast with other therapeutics, a high selectivity can be achieved with this combination.

35 If Re-188 is applied as the radionuclide, the damages will be much more severe than in the case of Tc-99m, but, consequently, the applied amount of radioactivity will be much lower than in case of "normal"

radiotherapy. Thus, severe side effects such as bone marrow toxicity could be avoided.

The present invention will be further illustrated in the examples that follow and which are
5 solely intended to clarify the invention, but are in no way intended to be limiting to the scope thereof.

In the Examples reference is made to the following figures:

Figure 1: schematic representation of potential
10 molecules of the invention.

Figure 2: example of a Tc(I) complex with this intercalating ligand and a potential biomolecule attached by direct linkage to another coordination site.

Figure 3: schematic representation of the
15 method for preparing molecules of the invention.

Figure 4: schematic representation of the three types of plasmid structures.

Figure 5: ethidium bromide stained agarose gel of the three types I, II and III of DNA (left lane) and a
20 molecular weight marker (right lane).

Figure 6: ethidium bromide stained agarose gel of a plasmid preparation treated with the compound $[^{99m}\text{Tc}(\text{P}_1)(\text{teta})(\text{CO})_3]$; The application site of the sample is on the bottom of the gel. Lane 1 is the molecular
25 weight marker; lane 2 is a reference solution containing supercoiled, relaxed (single strand break) and linearized (double strand break) plasmid, lane 3 is the experimental solution containing both plasmid and the intercalator of the invention, and lane 4 is the negative reference
30 containing only plasmid.

Figure 7: reaction scheme for the preparation of model bifunctional intercalators.

Figure 8: reaction scheme for the preparation of model trifunctional intercalators.

EXAMPLES**EXAMPLE 1**Synthesis of the molecules of the invention1. Introduction

5 To provide a strong intercalation, the intercalator should be preferably planar and aromatic heterocyclic. Furthermore, pendant groups in the intercalator must stably be coordinated to the radionuclide (i.e. ^{99m}Tc). In this example, it is not
10 coercive that the coordinating unit must be a multidentate ligand with high thermodynamic stability, since most complexes with Tc(I) show an extremely high kinetic stability. For these reasons and due to the already known principles of complexation of several mono-
15 and bidentate ligands (especially picolinic acid) 5,6-benzochinolin-3-carboxylic acid was selected as intercalator.

Figure 2 depicts an example of a Tc(I) complex with this intercalating ligand and a potential
20 biomolecule attached by direct linkage to another coordination site.

2. Synthesis of the example intercalator2.1. 3-cyano-4-benzoyl-3,4-dihydrobenzo(f)chinoline 2

25 648 μl (5.58 mmol) benzoyl chloride was added to a two phase system of water/methylene chloride over a period of two hours. These two layers contain 500 mg (2.79 mmol) of benzo(f)chinolin in the methylene chloride layer and 545 mg (8.37 mmol) KCN in water. Stirring was
30 continued for 6 hours. The organic phase was separated and washed with water, 5% hydrochloric acid, water, 5% NaOH solution, and again with water. After drying over magnesium sulfate, the solution was evaporated to dryness.

35 The bromide salt of this so-called Reissert-compound was recrystallized from 95% ethanol to yield the analytically pure substance. Yield: 612 mg (71%).

2.2 5,6-benzochinolin-3-carbon acid (P1)

2 ml 48% hydrobromide acid were added to 287 mg (0.93 mmol) of the Reissert-compound dissolved in 2 ml acetic acid. The solution was refluxed during 24 hours, cooled and filtered. The filtered product was washed with diethyl ether, dried, and recrystallized from methanol to yield 169 mg (0.76 mmol) (82%) of the hydrobromide of the intercalator as a yellow solid.

10 2.3 Macroscopic synthesis of Technetium and Rhenium complexes with P1 (5,6-benzochinolin-3-carbon acid)

2.3.1 $[\text{NEt}_4][\text{ReBr}(\text{P1})(\text{CO})_3]$

A suspension of 102 mg (133 μmol) $[\text{NEt}_4][\text{ReBr}_3(\text{CO})_3]$, 29.7 mg (133 μmol) P1 and 116 μl (226 mmol) of trioctylamine were refluxed in dichloromethane until a clear solution was achieved. After evaporation of the solution, the complex 5 was extracted into THF. After evaporization of THF the residue was washed with diethyl ether to remove trioctyl ammonium bromide. Yield: 63 mg (67%) of the yellow complex.

2.3.2 $[\text{Re}(\text{P}_1)(\text{H}_2\text{O})(\text{CO})_3]$

200.0 mg (0.26 μmol) of $[\text{NEt}_4]_2[\text{ReBr}_3(\text{CO})_3]$ were refluxed in the presence of 29.1 mg of the intercalator P1 during 4 hours in 1M MES-buffer solution. Then the yellow precipitation was filtered. Yield: 114.2 mg (86%).

2.4 Microscopic synthesis of $[\text{}^{99\text{m}}\text{Tc}(\text{H}_2\text{O})(\text{P}_1)(\text{CO})_3]$

The $^{99\text{m}}\text{Tc}$ complexes were synthesized in a two-step procedure with a normal generator eluate. In a first step the complex was synthesized in >97% yield according to the literature (R. Alberto et al., J. Am. Chem. Soc. 120, 7987 (1998)). The solution was then neutralized with phosphate buffer in the reaction vial and a solution of the corresponding ligand was added. The end concentration was between 10^{-4} and 10^{-5} . It was left standing for 30 minutes at 75°C. The radio-chemical purification and the yield were defined through HPLC-

chromatography and it was discovered that $[\text{}^{99\text{m}}\text{Tc}(\text{HPO}_4)(\text{P}_1)(\text{CO})_3]^{2-}$ (compound 10) with a yield of 80-95% (dependent on the ligand concentration and the reaction time) was formed.


5

2.5 Synthesis of model trifunctional molecules of the invention

This is an example how a trifunctional molecule can be built. The procedure is based on known synthetic approaches for the corresponding coupling methods. The schematic procedure is given in Figure 3.

1. Syntheses of the bifunctional ligands, bearing an intercalator and a coordinating functionality

15 A bifunctional ligand was prepared according to the strategy described in Fig. 3. Fig. 7 gives the specific reaction scheme of the reaction that is described hereinbelow.



2-Methylquinoline (1)

2-Methylquinoline (1) was bought from Fluka and used without further purification.

Quinoline-2-carbaldehyde (2)

A mixture of 5.5 g of selenium dioxide (49.5 mmol) in 50 ml dioxane and 2 ml water was added in small portions over 10 minutes to a boiling solution of 4.4 g (30.7 mmol) of 2-methylquinoline (1) in 20 ml dioxane. After 6 hours of boiling, the warm reaction mixture was filtered. The filtrate was evaporated, dissolved in

dichloromethane and filtered through Alox. The yellow-brown solid product obtained after evaporation of the solvent was recrystallized from dichloromethane. Yield: 3.76 g (78%)

5 $^1\text{H-NMR}$ (DMSO): δ , 10.12s, 8.61d, 8.22d, 8.12d, 7.99d, 7.91t, 7.79t

Compound 3a

A mixture of 500 mg of quinoline-2-carbaldehyde (2) (3.2 mmol) and 330mg of N-(2-aminoethyl)-acetamid (3.23 mmol) in 15 ml of methanol was stirred for 2 hours at room temperature. The light brown solid product obtained was directly used for the next reaction. Yield: ~770 mg (~100%)

15 $^1\text{H-NMR}$ (CDCl_3): δ , 8.57s, 8.21d, 8.13d, 8.10d, 7.85d, 7.75t, 7.59t

Compound 3b

A solution of 175 mg (4.62 mmol) of NaBH_4 in 10 ml of ethanol was slowly added over 2 hours to a stirred solution of 500 mg (2.07mmol) of 3a in 30 ml ethanol at 0°C. This mixture was then stirred overnight at room temperature. The solid substance obtained after evaporation of the solvent was triturated with a 3M Na_2CO_3 solution. The desired light brown product (3b) was then extracted with dichloromethane. Yield: 382 mg (76%)

$^1\text{H-NMR}$ (CDCl_3): δ , 8.15d, 8.05d, 7.81d, 7.71t, 7.54t, 7.35d, 6.84br, 4.21s, 3.50q, 3.02t, 2.02s

30 Compound 3c

A solution of 200 mg of 3b (0.82 mmol) in 20 ml of 2N HCl was refluxed for 6 hours. The oil obtained after evaporation of the solvent was washed with ethanol to give the desired light brown solid hydrochloride salt

35 3c. Yield: 203 mg (90%)

$^1\text{H-NMR}$ (D_2O): δ , 8.40d, 7.95t, 7.76t, 7.59t, 7.49d, 4.57s, 3.46t, 3.34t

N-BOC-diethylentriamine (4)

A solution of 500mg (2.29 mmol) of di-tert-butyl dicarbonate ((BOC)₂O) in 30 ml dioxan was slowly added to a solution of 1.49 ml (1.42 g) (13.74 mmol) of diethylentriamine in 80 ml of dioxan at 10°C. The mixture was then stirred for 15 hours at room temperature. The desired product precipitated as an oil, which was then separated from the rest of the solution, dissolved in water, filtered, and extracted with dichloromethane to finally give the desired product as a light yellow oil.

Yield: 260 mg (56%)

¹H-NMR (CDCl₃): δ, 5.15br, 3.25br, 3.18t, 2.77t, 2.69t, 2.63t, 1.76br, 1.41s, 1.19t

15 Compound 5a

A mixture of 140 mg of quinoline-2-carbaldehyde (2) (0.89 mmol) and 200mg of N-BOC-diethylentriamine (0.99 mmol) in 30 ml of methanol was stirred for 3 hours at room temperature. The solid obtained after evaporation of the solvent was then washed with water to obtain the desired light brown product. Yield: 304 mg (94%)

¹H-NMR (DMSO): δ, 8.32d, 7.97t, 7.73t, 7.71d, 7.57t, 6.65t, 4.33s, 3.08t, 2.97t, 2.85t, 1.28s, 1.09t

25 Compound 5b

A solution of 41 mg (1.08 mmol) of NaBH₄ in 10 ml of ethanol was slowly added over 2 hours to a stirred solution of 148 mg (0.43mmol) 5a in 30 ml of ethanol at 0°C. This mixture was then stirred overnight at room temperature. The solid brown oil obtained after evaporation of the solvent was triturated with a 3M Na₂CO₃ solution. The desired light brown product (3b) was then extracted with dichloromethane. Yield: 136 mg (92%)

¹H-NMR (DMSO): δ, 8.29d, 7.94d, 7.92d, 7.71t, 7.61d, 7.54t, 6.71t, 3.95s, 2.96q, 2.59s, 1.33s, 1.22t


Compound 5c

A solution of 100 mg of **5b** (0.29 mmol) in 3N HCl was refluxed for 2 hours. The oil obtained after evaporation of the solvent was washed with diethylether to give the desired light brown solid hydrochloride salt **5c**. Yield: 102 mg (94%)

$^1\text{H-NMR}$ (D_2O): δ , 8.44d, 7.95t, 7.77t, 7.6t, 7.51d, 4.51s, 3.44s, 3.34t, 3.27t

10 2. **Synthesis of trifunctional model intercalators**

Trifunctional intercalators were prepared starting from **5a** or **3b** of part 1 above. Fig. 8 gives the specific reaction scheme.



1. **alkylation of an amine with bromo-aceticacid-ethylester**

25 Amine I (Fig. 7; 547 mg, 2.83 mmol) and triethylene amine (0.510 ml, 3.08 mmol) were stirred in methanol (10 ml). The solution was cooled to 0°C, and ethyl bromoacetate II (0.313 ml, 2.83 mmol) was added dropwise within 5 minutes. After stirring the solution at
30 room temperature for 18 hours, the solvent was removed in vacuo. The residue was dissolved in dichloromethane (50 ml) and washed three times with water (20 ml). The water phases were washed twice with dichloromethane (50 ml). The organic phases were dried over MgSO_4 , filtered, and
35 the solvent was removed in vacuo to give III as a yellow oil. Yield: 590 mg (2.11 mmol, 74.6%).
TLC (silica, ethanol) R_f 0.4

¹H NMR (200 MHz, d₆-acetone) δ = 8.44 (m, 1H, picolin), 7.65 (m, 1H, picolin), 7.45 (m, 1H, picolin), 7.21 (m, 1H, picolin), 4.12 (q, 2 H, J = 7.2 Hz, CH₂ ester), 3.94 (s, 2H, CH₂), 3.64 (s, 2H, CH₂), 3.32 (m, 2H, N-CH₂-CH₂-N), 2.82 (m, 2H, N-CH₂-CH₂-N), 1.84 (s, 3H, CH₃-CO), 1.21 (t, 3H, J = 7.2 Hz, CH₃ ester).

2. deprotection

Amine III (576 mg, 1.94 mmol) was dissolved in ethanol (4 ml) and water (8 ml). NaOH 2M (2 ml) was added, and the solution was stirred at room temperature for 1.5 hours. Analytical HPLC exhibited a single peak, indicating that the ester group was cleaved quantitatively.

The solvent was removed in vacuo, the residue was dissolved in water (8 ml), and HCl 2N (1 ml) was added to neutralize the solution. HCl 33% (1.0 ml) was added, and the reaction mixture was stirred at 90°C for 48 hours. NaHCO₃ was added to neutralize the reaction mixture, the solvent was removed in vacuo and the residue was washed with ethanol. Removing of the solvent gave the deprotected product V as a yellow oil. Yield: 352 mmol (1.68 mmol, 68.6%).

¹H NMR (300 MHz, D₂O) δ = 8.44 (m, 1H, picolin), 7.85 (m, 1H, picolin), 7.45 (m, 1H, picolin), 7.39 (m, 1H, picolin), 3.78 (s, 2H, CH₂), 3.35 (m, 2H, N-CH₂-CH₂-N), 3.22 (s, 2H, CH₂), 3.32), 2.79 (m, 2H, N-CH₂-CH₂-N).

30 **EXAMPLE 2**

Strand breaking with the molecules of the invention in a model system

1. **Introduction**

1.1 The use of plasmids

To investigate the ability of the intercalating complexes with ^{99m}Tc to induce DNA-strandbreaks, plasmids were used as a model system. Plasmids are very suitable because electrophoretic analyses allow to differentiate

between double and single strand breaks. Additionally, large quantities of plasmids can be produced very simply by using cell biological methods.

A plasmid is a circular double-stranded DNA molecule, which double helical axis can be drilled into a superhelix. This form of the superhelix is described as type I. This type may lose its superhelix-structure by a single strandbreak and is then present as a relaxed circular DNA (type II). Through a double strandbreak of both types a linear form (type III) of the plasmid will be created. Figure 4 shows an example of the structure of these 3 DNA types.

Because these three DNA types have different structures, they may well be separated due to their size and especially their form by electrophoresis on agarose gel. The mixture (type I-III after the experiment) to be investigated is loaded on an agarose gel. A constant voltage will then be applied and the negatively charged DNA-fragments will migrate toward the cathode. The larger the form of the fragment, the slower the migration along the gel. DNA of type I (most compact) moves fastest, type II slowest. The gel will then be put in solution which contains very little ethidium bromide. The DNA fragments are made visible by intercalation and irradiation with UV-light of 300 nm depicting red-orange colored fluorescence (590 nm). This method is so sensitive that less than 5 ng DNA per band are detected. In the photographic record of the gels in Figure 5, the migration direction is from the top to the bottom.

1.2 Production of the plasmids

The plasmid Bluescript KSTM with a size of 2958 base pairs has been produced following the standard protocol of the company QIAGEN. Usually, this plasmid exists in the superhelix form (type I). With the restriction enzyme KpnI the linearized form of the plasmid DNA (type III) can be produced. A single strandbreak resulting in the relaxed circular form of

plasmid (type II), can be induced by the enzyme DNAase I. Figure 5, right lane, shows the electrophoresis on agarose-gel of a mixture of these three types of DNA. For the electrophoresis a marker with several sizes of DNA-
5 pieces has been used as reference (left lane).

As demonstrated by the three bands of the right lane, the three types of DNA were clearly separated and can be distinguished after visualization. If single or double strand breaks result from conversion electrons, it
10 should be easy detectable by this method.

2. Investigation of the ability of [$^{99m}\text{Tc}(\text{P}_1)(\text{teta})(\text{CO})_3$] to induce strandbreaks

5 μl of a solution containing approx. 0.3 mCi/
15 ml of [$^{99m}\text{Tc}(\text{P}_1)(\text{teta})(\text{CO})_3$] and 100 ng of type I plasmid ($\sim 3 \cdot 10^5$ M in base pairs) were left standing over a period of 18 hours. Then a electrophoresis of this mixture and the three references was made (Figure 6).

It is clearly visible that the plasmids in the
20 measurement solution (lane 3) migrate slower than in the reference solution. The reason for this observation is that a small change in the structure of the plasmids is probably induced by intercalation of the complex into the double strand. This change in the tertiary structure of
25 the plasmid did then allow a better intercalation of the ethidium bromide, thus explaining the stronger intensity of the band of sample solution.

Furthermore, in the comparison with the negative reference solution (lane 4), it is obvious that
30 one or possibly two new bands appeared (arrows) in the lane of the solution treated with the ^{99m}Tc complex. The stronger of these two bands corresponds approximately to the position of type II on the band of reference solution in lane 2, containing the three types. This means that
35 the complex has induced a single strand break in the plasmid.

CLAIMS

1. Molecules for treatment and diagnosis of tumors and malignancies, comprising a tumor seeking biomolecule, which is coupled to an intercalating moiety, which is capable of complexing a metal, which metal is
5 preferably a radioactive metal.

2. Molecules as claimed in claim 1 wherein the biomolecule is selected from the group consisting of somatostatin-, neurotensin-, bombesin-receptor binding molecules, antibodies, penetratinesTM, and molecules
10 binding to the GPIIb/IIIa receptors.

3. Molecules as claimed in claims 1 and 2 wherein the intercalating agent is an aromatic molecule with an intercalative binding affinity for double-stranded DNA.

15 4. Molecules as claimed in claim 3, wherein the intercalating agent is selected from the group consisting of acridine, porphyrin, ellipticine, phenantroline, carbazole, benzimidazole or compounds with known cytostatic activity (antibiotics) from the class of
20 tetracyclines (anthracyclines), such as daunorubicine, epirubicine or mixoxantrone.

5. Molecules as claimed in claims 1-4, wherein the radioactive metal is a γ -emitting nuclide.

6. Molecules as claimed in claim 5, wherein the
25 radioactive metal is selected from the group consisting of Tc-99m, Re-186, Re-188 and Mn.

7. Molecules as claimed in claims 1-6 having the general structural formula as given in Fig. 2.

8. Molecule as claimed in claims 1-7, having
30 any one of the structures as shown in Fig. 1.


9. Molecules as claimed in claims 1-8 for use as or in a therapeutic or diagnostic agent for treating or diagnosing tumors or malignancies.

10. Use of molecules as claimed in claims 1-8
35 for the preparation of a therapeutic or diagnostic agent for treating or diagnosing cancer tumors or malignancies.


11. Therapeutical composition, comprising one or more molecules as claimed in claims 1-8 and one or more suitable excipients.


12. Diagnostic composition, comprising one or 5 more molecules as claimed in claims 1-8 in a suitable carrier.

1/7



2/7

FIG. 2

**FIG. 3**

4/7




FIG. 4

BEST AVAILABLE COPY

5/7




FIG. 6





FIG. 5

BEST AVAILABLE COPY

6/7

Reaction Scheme

**FIG. 7**

FIG. 8

INTERNATIONAL SEARCH REPORT

Application No
PCT/EP 00/01553

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K47/48 A61K51/10 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, MEDLINE, EMBASE, BIOSIS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| X | BHALGAT M K ET AL: "Preparation and biodistribution of copper-67-labeled porphyrins and porphyrin -A6H immunoconjugates." NUCLEAR MEDICINE AND BIOLOGY, vol. 24, no. 2, February 1997 (1997-02), pages 179-185, XP000682959 abstract | 1-6,9-12 |
| Y | --- | 7,8 |
| X | FAWWAZ, R. A. ET AL: "The use of a porphyrin bifunctional chelator for labeling of a monoclonal antibody with radioactive manganese" JOURNAL OF NUCLEAR MEDICINE: PROCEEDINGS OF THE 36TH ANNUAL MEETING, vol. 30, 1989, pages 935-936, XP000915982 abstract | 1-6,9-12 |
| Y | --- | 7,8 |
| | -/-- | |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

10 July 2000

Date of mailing of the international search report

18/07/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Pilling, S

INTERNATIONAL SEARCH REPORT

 at Application No
 PCT/EP 00/01553

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| X | MERCER-SMITH J A ET AL: "The biodistribution of radiocopper-labeled compounds." ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, (1989) 258 103-21. , vol. 258, 1989, pages 103-121, XP000916022 | 1-6,9-12 |
| Y | abstract | 7,8 |
| X | LEWIS D ET AL: "The cytotoxicity of copper-67 porphyrin-antibody conjugates to a colon carcinoma cell line" ABSTRACTS OF PAPERS AMERICAN CHEMICAL SOCIETY, vol. 202, 25 - 30 August 1991, page Biot 168 XP000916021 | 1-6,9-12 |
| Y | abstract | 7,8 |
| X | US 5 171 749 A (LEVY JULIA G ET AL) 15 December 1992 (1992-12-15) | 1-6,9-12 |
| Y | column 4, line 13 -column 4, line 27; example 5 | 7,8 |
| X | WO 93 21957 A (STERLING WINTHROP INC) 11 November 1993 (1993-11-11) | 1-6,9-12 |
| Y | page 6, line 3 - line 10 | 7,8 |
| X | US 5 759 514 A (MATTES M JULES) 2 June 1998 (1998-06-02) | 1-6,9-12 |
| | column 2, line 22 -column 2, line 61 | |
| X | PIMM M V ET AL: "Biodistribution and tumour localisation of a daunomycin-monoclonal antibody conjugate in nude mice with human tumour xenografts." CANCER IMMUNOLOGY, IMMUNOTHERAPY , vol. 27, no. 3, 1988, pages 267-271, XP000915990 | 1-6,9-12 |
| | abstract | |
| X | TRAIL, P A: "Site directed delivery of anthracyclines for treatment of cancer" DRUG DEVELOPMENT RESEARCH, vol. 34, no. 2, February 1995 (1995-02), pages 196-209, XP000916019 | 1-6,9-12 |
| | abstract | |
| Y | EP 0 879 606 A (SCHERRER INST PAUL) 25 November 1998 (1998-11-25) cited in the application page 2, line 25 - line 33; example 3 | 7,8 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

Application No
PCT/EP 00/01553

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|---------------------|
| US 5171749 A | 15-12-1992 | US 4883790 A | 28-11-1989 |
| | | US 4920143 A | 24-04-1990 |
| | | US 5399583 A | 21-03-1995 |
| | | US 5283255 A | 01-02-1994 |
| | | AT 104859 T | 15-05-1994 |
| | | AU 618725 B | 09-01-1992 |
| | | AU 1038888 A | 21-07-1988 |
| | | CA 1333442 A | 06-12-1994 |
| | | DE 3889231 D | 01-06-1994 |
| | | DE 3889231 T | 11-08-1994 |
| | | EP 0276121 A | 27-07-1988 |
| | | ES 2055735 T | 01-09-1994 |
| | | JP 1999536 C | 08-12-1995 |
| | | JP 6008319 B | 02-02-1994 |
| | | JP 63277700 A | 15-11-1988 |
| | | JP 2835294 B | 14-12-1998 |
| | | JP 7258262 A | 09-10-1995 |
| | | MX 9203250 A | 31-07-1992 |
| | | US 5095030 A | 10-03-1992 |
| | | AT 127696 T | 15-09-1995 |
| | | AU 638675 B | 08-07-1993 |
| | | AU 3825889 A | 08-02-1990 |
| | | DE 68924215 D | 19-10-1995 |
| | | DE 68924215 T | 15-02-1996 |
| | | EP 0352076 A | 24-01-1990 |
| | | EP 0641796 A | 08-03-1995 |
| | | ES 2080745 T | 16-02-1996 |
| | | GR 3017426 T | 31-12-1995 |
| | | JP 2149519 A | 08-06-1990 |
| | | JP 7080887 B | 30-08-1995 |
| | | NO 179410 B | 24-06-1996 |
| WO 9321957 A | 11-11-1993 | CA 2135059 A | 11-11-1993 |
| | | AU 2316192 A | 29-11-1993 |
| | | BR 9207126 A | 29-08-1995 |
| | | EP 0639083 A | 22-02-1995 |
| | | FI 945194 A | 04-01-1995 |
| | | JP 7506667 T | 20-07-1995 |
| | | NO 944182 A | 21-12-1994 |
| US 5759514 A | 02-06-1998 | RU 2122431 C | 27-11-1998 |
| | | AU 2284595 A | 29-11-1995 |
| | | CA 2189051 A | 09-11-1995 |
| | | EP 0757559 A | 12-02-1997 |
| | | JP 10503478 T | 31-03-1998 |
| EP 0879606 A | 25-11-1998 | WO 9529707 A | 09-11-1995 |
| | | AU 7141398 A | 24-11-1998 |
| | | NO 995160 A | 13-12-1999 |
| | | WO 9848848 A | 05-11-1998 |